Article
Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
Annals of clinical biochemistry - 1 Jan 2003
van Kuilenburg André B P, De Abreu Ronney A, van Gennip Albert H
Abstract excerpt
Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5FU). A deficiency of DPD is increasingly being recognized as the cause of an important pharmacogenetic syndrome. The importance of DPD deficiency in the aetiology of unexpected severe 5FU toxicity has been demonstrated by the fact that, in 39-59% of cases, decreased DPD activity could be detected in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
